NICE Should Revise Assessment Process After Relenza Review, ABPI Says
Executive Summary
The Association of the British Pharmaceutical Industry is proposing an alternative procedure for the U.K.' s National Institute of Clinical Excellence to follow in its new drug assessments, following NICE's Oct. 8 decision to recommend against prescribing Glaxo Wellcome's Relenza for the 1999 flu season.
You may also be interested in...
Tamiflu DTC Ads Should Encourage Flu Vaccination, FDA's Jolson Suggests
Direct-to-consumer advertising for Roche/Gilead's Tamiflu should emphasize the importance of influenza vaccination, FDA Antiviral Drug Products Division Director Heidi Jolson, MD, said in a memo explaining FDA's rationale for approving the flu treatment.
Tamiflu DTC Ads Should Encourage Flu Vaccination, FDA's Jolson Suggests
Direct-to-consumer advertising for Roche/Gilead's Tamiflu should emphasize the importance of influenza vaccination, FDA Antiviral Drug Products Division Director Heidi Jolson, MD, said in a memo explaining FDA's rationale for approving the flu treatment.
WellPoint Hopes To Curb Relenza Costs By Pushing Flu Vaccination
WellPoint Health Networks is encouraging flu vaccinations in 280,000 letters to members, as part of a campaign to limit use of Glaxo Wellcome's influenza treatment Relenza.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: